Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 8,942	$ 5,618
Marketable securities	2,348	14,106
Accounts receivable, net	628	639
Prepaid expenses and other current assets	832	1,061
Total current assets	12,750	21,424
Property and equipment, net	544	604
TOTAL ASSETS	13,294	22,028
Current liabilities:
Accounts payable	2,439	2,322
Accrued expenses	4,520	4,364
TOTAL LIABILITIES	6,959	6,686
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 11,476,601 shares issued as of March 31, 2019 and December 31, 2018; 11,475,749 shares outstanding as of March 31, 2019 and December 31, 2018	1	1
Additional paid-in capital	208,216	208,156
Treasury stock, at cost; 852 shares of common stock as of March 31, 2019 and December 31, 2018	(11)	(11)
Accumulated deficit	(225,834)	(216,767)
Total Vaccinex, Inc. stockholders’ deficit	(17,628)	(8,621)
Noncontrolling interests	23,963	23,963
TOTAL STOCKHOLDERS’ EQUITY	6,335	15,342
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 13,294	$ 22,028